Table 1 The baseline characteristics of the 39 participants
Mean age (years) | 65 |
|---|---|
Histology (clear cell/papillary) | 38/1 |
Prognostic risk | |
MSKCC (low/intermediate/high) | 8/24/4 |
Heng (low/intermediate/high) | 7/21/8 |
ECOG performance status (0-1/>1) | 33/6 |
Treatment with | |
sorafenib/sunitinib/pazopanib | 19/18/2 |
Nephrectomy (y/n) | 37/2 |
Prior treatment | |
None | 20 |
Interferon-alpha | 7 |
sunitinib | 11 |
Chemotherapy | 1 |